BMGL — Basel Medical Income Statement
0.000.00%
- $17.34m
- $12.40m
- SG$11.32m
Annual income statement for Basel Medical, fiscal year end - June 30th, SGD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 10.7 | 9.7 | 10.1 | 11.3 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 6.33 | 5.41 | 5.63 | 22.2 |
| Operating Profit | 4.33 | 4.29 | 4.42 | -10.9 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 2.39 | 2.13 | 2.4 | -12.5 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 1.98 | 1.78 | 2.07 | -12.1 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 1.98 | 1.78 | 2.07 | -12.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 1.98 | 1.78 | 2.07 | -12.1 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.107 | 0.097 | 0.112 | -0.258 |